{"id":62163,"date":"2026-09-28T21:05:12","date_gmt":"2026-09-28T21:05:12","guid":{"rendered":"https:\/\/www.parkinson.ca\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/"},"modified":"2026-09-28T22:17:17","modified_gmt":"2026-09-28T22:17:17","slug":"la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir","status":"publish","type":"post","link":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/","title":{"rendered":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu&rsquo;il s&rsquo;agisse d&rsquo;une nouvelle encourageante, <strong>le tavapadon n&rsquo;est actuellement ni approuv\u00e9 ni disponible au Canada.<\/strong> Voici ce que vous devez savoir. <\/p>\n\n\n\n<div style=\"height:5px\" aria-hidden=\"true\" class=\"wp-block-spacer is-style-responsive-xsmall\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-regular-font-size\"><strong>Qu&rsquo;est-ce que<\/strong><strong> <\/strong><strong>le tavapadon ?<\/strong> <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Le tavapadon est un comprim\u00e9 \u00e0 prise quotidienne unique, d\u00e9velopp\u00e9 par AbbVie, qui appartient \u00e0 un groupe de m\u00e9dicaments appel\u00e9s agonistes dopaminergiques. Ces m\u00e9dicaments imitent les effets de la dopamine, une substance chimique du cerveau qui aide \u00e0 contr\u00f4ler les mouvements et qui est r\u00e9duite chez les personnes vivant avec la maladie de Parkinson. <\/p>\n\n\n\n<div style=\"height:5px\" aria-hidden=\"true\" class=\"wp-block-spacer is-style-responsive-xsmall\"><\/div>\n\n\n\n<h1 class=\"wp-block-heading has-regular-font-size\"><strong>Pourquoi cette approbation est-elle notable ?<\/strong> <\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Contrairement \u00e0 la plupart des agonistes dopaminergiques existants, qui ciblent les r\u00e9cepteurs dopaminergiques appel\u00e9s D2 et D3, le tavapadon cible s\u00e9lectivement les r\u00e9cepteurs dopaminergiques appel\u00e9s D1 et D5. Le tavapadon est le premier m\u00e9dicament de ce type \u00e0 recevoir l&rsquo;approbation de la FDA. Cette approche unique offre une voie suppl\u00e9mentaire pour g\u00e9rer m\u00e9dicalement les sympt\u00f4mes des personnes vivant avec la maladie de Parkinson. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Il est important de noter que le tavapadon aide \u00e0 g\u00e9rer les sympt\u00f4mes, mais qu&rsquo;il n&rsquo;a pas \u00e9t\u00e9 d\u00e9montr\u00e9 qu&rsquo;il ralentit ou arr\u00eate la progression de la maladie de Parkinson.<\/strong> <\/p>\n\n\n\n<div style=\"height:5px\" aria-hidden=\"true\" class=\"wp-block-spacer is-style-responsive-xsmall\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-regular-font-size\"><strong>Quelles preuves ont soutenu l&rsquo;approbation de la FDA ?<\/strong> <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L&rsquo;approbation a \u00e9t\u00e9 soutenue par trois essais cliniques de phase 3, connus sous les noms de TEMPO-1, TEMPO-2 et TEMPO-3, qui ont \u00e9valu\u00e9 le tavapadon \u00e0 diff\u00e9rents stades du parcours des personnes atteintes de la maladie de Parkinson. <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TEMPO-1 et TEMPO-2<\/strong> ont \u00e9tudi\u00e9 des personnes atteintes de la maladie de Parkinson \u00e0 un stade pr\u00e9coce qui ne prenaient pas de l\u00e9vodopa. Les deux essais ont r\u00e9v\u00e9l\u00e9 que le tavapadon am\u00e9liorait les sympt\u00f4mes moteurs et la capacit\u00e9 \u00e0 effectuer les activit\u00e9s quotidiennes. <\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TEMPO-3<\/strong> a \u00e9tudi\u00e9 des personnes prenant d\u00e9j\u00e0 de la l\u00e9vodopa qui connaissaient des p\u00e9riodes pendant lesquelles leur m\u00e9dicament \u00e9tait moins efficace. L&rsquo;ajout de tavapadon a fourni environ une heure suppl\u00e9mentaire chaque jour pendant laquelle les sympt\u00f4mes \u00e9taient bien contr\u00f4l\u00e9s, sans mouvements involontaires g\u00eanants. <\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Il convient de noter que l&rsquo;essai mondial TEMPO-1 comprenait deux sites de recherche canadiens, situ\u00e9s \u00e0 Ottawa et \u00e0 Toronto. L&rsquo;\u00e9tude est maintenant termin\u00e9e et ferm\u00e9e aux nouveaux participants. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ensemble, ces r\u00e9sultats d\u00e9montrent le potentiel du tavapadon pour aider \u00e0 g\u00e9rer les sympt\u00f4mes moteurs \u00e0 diff\u00e9rents stades du parcours de la maladie de Parkinson. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Consultez les r\u00e9sultats publi\u00e9s des essais cliniques : <a href=\"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2846846\" target=\"_blank\" rel=\"noreferrer noopener\">TEMPO-1<\/a>, <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42456682\/\" target=\"_blank\" rel=\"noreferrer noopener\">TEMPO-2<\/a> et <a href=\"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2846847\" target=\"_blank\" rel=\"noreferrer noopener\">TEMPO-3<\/a> (en anglais).<\/p>\n\n\n\n<div style=\"height:5px\" aria-hidden=\"true\" class=\"wp-block-spacer is-style-responsive-xsmall\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-regular-font-size\"><strong>Que signifie cette approbation pour les personnes vivant avec la maladie de Parkinson au Canada ?<\/strong> <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bien que la FDA ait approuv\u00e9 le tavapadon le 25 septembre 2026, cette autorisation s&rsquo;applique uniquement aux \u00c9tats-Unis. AbbVie pr\u00e9voit de rendre le m\u00e9dicament disponible aux personnes aux \u00c9tats-Unis en octobre 2026. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On ne sait pas encore si AbbVie demandera une approbation au Canada ou quand le tavapadon pourrait devenir disponible ici. Tous les m\u00e9dicaments approuv\u00e9s aux \u00c9tats-Unis ne deviennent pas disponibles au Canada. Cela peut d\u00e9pendre du fait que le fabricant demande ou non l&rsquo;approbation canadienne, du processus d&rsquo;examen de Sant\u00e9 Canada et des d\u00e9cisions concernant la mise sur le march\u00e9 canadien du m\u00e9dicament. Avant qu&rsquo;un nouveau m\u00e9dicament puisse \u00eatre prescrit et vendu au Canada, il doit faire l&rsquo;objet d&rsquo;un examen r\u00e9glementaire de Sant\u00e9 Canada et recevoir une autorisation. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Si vous avez des questions concernant vos m\u00e9dicaments, parlez-en \u00e0 votre neurologue ou \u00e0 votre \u00e9quipe de soins de sant\u00e9. <\/p>\n\n\n\n<div style=\"height:5px\" aria-hidden=\"true\" class=\"wp-block-spacer is-style-responsive-xsmall\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-regular-font-size\"><strong>Perspectives d&rsquo;avenir<\/strong> <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Les nouvelles approbations de traitements sont importantes car elles \u00e9largissent l&rsquo;\u00e9ventail d&rsquo;options disponibles pour les personnes vivant avec la maladie de Parkinson. M\u00eame lorsqu&rsquo;un m\u00e9dicament n&rsquo;est pas encore disponible au Canada, ces d\u00e9veloppements contribuent \u00e0 faire progresser les soins de la maladie de Parkinson et peuvent influencer les futurs choix de traitement. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Parkinson Canada continuera de surveiller les d\u00e9veloppements li\u00e9s au tavapadon et \u00e0 d&rsquo;autres traitements \u00e9mergents, notamment en s&rsquo;engageant aupr\u00e8s d&rsquo;AbbVie pour en savoir plus sur le potentiel du tavapadon \u00e0 devenir disponible au Canada, tout en plaidant pour un acc\u00e8s rapide aux m\u00e9dicaments et \u00e0 des soins de qualit\u00e9 pour les personnes vivant avec la maladie de Parkinson partout au Canada. <\/p>\n\n\n\n<div style=\"height:5px\" aria-hidden=\"true\" class=\"wp-block-spacer is-style-responsive-xsmall\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-regular-font-size\"><strong>Ressources suppl\u00e9mentaires<\/strong> <\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/news.abbvie.com\/2026-09-28-U-S-FDA-Approves-AbbVies-JUVMO-TM-tavapadon-for-Parkinsons-Disease\" target=\"_blank\" rel=\"noreferrer noopener\">Annonce d&rsquo;approbation de la FDA par AbbVie<\/a> (en anglais)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.canada.ca\/fr\/sante-canada\/services\/medicaments-produits-sante\/medicaments\/feuillets-information\/comment-medicaments-sont-examines-canada.html\" target=\"_blank\" rel=\"noopener\">Comment les m\u00e9dicaments sont examin\u00e9s au Canada &#8211; Canada.ca<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu&rsquo;il s&rsquo;agisse d&rsquo;une nouvelle encourageante, le tavapadon n&rsquo;est actuellement ni approuv\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu&rsquo;est-ce que le tavapadon ? Le tavapadon est un comprim\u00e9 [&hellip;]<\/p>\n","protected":false},"author":235,"featured_media":62165,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[64,237,246],"tags":[],"audience":[],"class_list":["post-62163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites","category-blogue-fr","category-recherche-blog"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu&#039;il s&#039;agisse d&#039;une nouvelle encourageante, le tavapadon n&#039;est actuellement ni approuv\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu&#039;est-ce que le tavapadon ? Le tavapadon est un comprim\u00e9\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Sarah Parsons\"\/>\n\t<meta name=\"google-site-verification\" content=\"2AhivUiST2eKQcfei6JBM5Zbf8YQRvHy0kRBp9sDLWo\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Parkinson Canada -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir - Parkinson Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu&#039;il s&#039;agisse d&#039;une nouvelle encourageante, le tavapadon n&#039;est actuellement ni approuv\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu&#039;est-ce que le tavapadon ? Le tavapadon est un comprim\u00e9\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-09-28T21:05:12+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-09-28T22:17:17+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:title\" content=\"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir - Parkinson Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu&#039;il s&#039;agisse d&#039;une nouvelle encourageante, le tavapadon n&#039;est actuellement ni approuv\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu&#039;est-ce que le tavapadon ? Le tavapadon est un comprim\u00e9\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#blogposting\",\"name\":\"La FDA approuve le tavapadon : ce que la communaut\\u00e9 Parkinson au Canada doit savoir - Parkinson Canada\",\"headline\":\"La FDA approuve le tavapadon : ce que la communaut\\u00e9 Parkinson au Canada doit savoir\",\"author\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/sarah-parsonsparkinson-ca\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/FDA-Approves-Tavapadon-1-scaled.png\",\"width\":2560,\"height\":1440,\"caption\":\"La FDA approuve le tavapadon\"},\"datePublished\":\"2026-09-28T21:05:12+00:00\",\"dateModified\":\"2026-09-28T22:17:17+00:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s, Blogue, Recherche, Facultatif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/actualites\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s\",\"item\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/actualites\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#listItem\",\"name\":\"La FDA approuve le tavapadon : ce que la communaut\\u00e9 Parkinson au Canada doit savoir\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#listItem\",\"position\":3,\"name\":\"La FDA approuve le tavapadon : ce que la communaut\\u00e9 Parkinson au Canada doit savoir\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\",\"name\":\"Parkinson Canada\",\"description\":\"Parkinson Canada empowers people living with Parkinson\\u2019s and their care partners to thrive. Through advocacy, education, and support, we work to improve access to care, advance research, and build a stronger Parkinson\\u2019s community across Canada. Join us in making a difference.\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"email\":\"info@parkinson.ca\",\"telephone\":\"+18005653000\",\"foundingDate\":\"1965-04-11\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/parkinson.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Parkinson-Canada-logo-23-RGB.jpg\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/parkinsoncanada\",\"https:\\\/\\\/twitter.com\\\/parkinsoncanada\",\"https:\\\/\\\/instagram.com\\\/parkinsoncanada\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm_sAjRqhAaiutx2B9dOqng\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/parkinson-canada\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/sarah-parsonsparkinson-ca\\\/#author\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/sarah-parsonsparkinson-ca\\\/\",\"name\":\"Sarah Parsons\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/40c3ba45b86209e51a59927654bd4c8422d131424478453c113e3c795a19a147?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Sarah Parsons\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#webpage\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/\",\"name\":\"La FDA approuve le tavapadon : ce que la communaut\\u00e9 Parkinson au Canada doit savoir - Parkinson Canada\",\"description\":\"La Food and Drug Administration (FDA) des \\u00c9tats-Unis a approuv\\u00e9 un nouveau m\\u00e9dicament pour la maladie de Parkinson appel\\u00e9 tavapadon (nom commercial JUVMO\\u2122). Bien qu'il s'agisse d'une nouvelle encourageante, le tavapadon n'est actuellement ni approuv\\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu'est-ce que le tavapadon ? Le tavapadon est un comprim\\u00e9\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/sarah-parsonsparkinson-ca\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/sarah-parsonsparkinson-ca\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/FDA-Approves-Tavapadon-1-scaled.png\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#mainImage\",\"width\":2560,\"height\":1440,\"caption\":\"La FDA approuve le tavapadon\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\\\/#mainImage\"},\"datePublished\":\"2026-09-28T21:05:12+00:00\",\"dateModified\":\"2026-09-28T22:17:17+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"name\":\"Parkinson Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir - Parkinson Canada","description":"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu'il s'agisse d'une nouvelle encourageante, le tavapadon n'est actuellement ni approuv\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu'est-ce que le tavapadon ? Le tavapadon est un comprim\u00e9","canonical_url":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"2AhivUiST2eKQcfei6JBM5Zbf8YQRvHy0kRBp9sDLWo","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#blogposting","name":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir - Parkinson Canada","headline":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir","author":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/sarah-parsonsparkinson-ca\/#author"},"publisher":{"@id":"https:\/\/www.parkinson.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2026\/09\/FDA-Approves-Tavapadon-1-scaled.png","width":2560,"height":1440,"caption":"La FDA approuve le tavapadon"},"datePublished":"2026-09-28T21:05:12+00:00","dateModified":"2026-09-28T22:17:17+00:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#webpage"},"isPartOf":{"@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#webpage"},"articleSection":"Actualit\u00e9s, Blogue, Recherche, Facultatif"},{"@type":"BreadcrumbList","@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/#listItem","position":1,"name":"Home","item":"https:\/\/www.parkinson.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/#listItem","name":"Actualit\u00e9s"}},{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/#listItem","position":2,"name":"Actualit\u00e9s","item":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#listItem","name":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#listItem","position":3,"name":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir","previousItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/#listItem","name":"Actualit\u00e9s"}}]},{"@type":"Organization","@id":"https:\/\/www.parkinson.ca\/fr\/#organization","name":"Parkinson Canada","description":"Parkinson Canada empowers people living with Parkinson\u2019s and their care partners to thrive. Through advocacy, education, and support, we work to improve access to care, advance research, and build a stronger Parkinson\u2019s community across Canada. Join us in making a difference.","url":"https:\/\/www.parkinson.ca\/fr\/","email":"info@parkinson.ca","telephone":"+18005653000","foundingDate":"1965-04-11","numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"logo":{"@type":"ImageObject","url":"https:\/\/parkinson.ca\/wp-content\/uploads\/2025\/01\/Parkinson-Canada-logo-23-RGB.jpg","@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#organizationLogo"},"image":{"@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#organizationLogo"},"sameAs":["https:\/\/facebook.com\/parkinsoncanada","https:\/\/twitter.com\/parkinsoncanada","https:\/\/instagram.com\/parkinsoncanada","https:\/\/www.youtube.com\/channel\/UCm_sAjRqhAaiutx2B9dOqng","https:\/\/www.linkedin.com\/company\/parkinson-canada"]},{"@type":"Person","@id":"https:\/\/www.parkinson.ca\/fr\/author\/sarah-parsonsparkinson-ca\/#author","url":"https:\/\/www.parkinson.ca\/fr\/author\/sarah-parsonsparkinson-ca\/","name":"Sarah Parsons","image":{"@type":"ImageObject","@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/40c3ba45b86209e51a59927654bd4c8422d131424478453c113e3c795a19a147?s=96&d=mm&r=g","width":96,"height":96,"caption":"Sarah Parsons"}},{"@type":"WebPage","@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#webpage","url":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/","name":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir - Parkinson Canada","description":"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu'il s'agisse d'une nouvelle encourageante, le tavapadon n'est actuellement ni approuv\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu'est-ce que le tavapadon ? Le tavapadon est un comprim\u00e9","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/www.parkinson.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#breadcrumblist"},"author":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/sarah-parsonsparkinson-ca\/#author"},"creator":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/sarah-parsonsparkinson-ca\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2026\/09\/FDA-Approves-Tavapadon-1-scaled.png","@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#mainImage","width":2560,"height":1440,"caption":"La FDA approuve le tavapadon"},"primaryImageOfPage":{"@id":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/#mainImage"},"datePublished":"2026-09-28T21:05:12+00:00","dateModified":"2026-09-28T22:17:17+00:00"},{"@type":"WebSite","@id":"https:\/\/www.parkinson.ca\/fr\/#website","url":"https:\/\/www.parkinson.ca\/fr\/","name":"Parkinson Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/www.parkinson.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Parkinson Canada -","og:type":"article","og:title":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir - Parkinson Canada","og:description":"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu'il s'agisse d'une nouvelle encourageante, le tavapadon n'est actuellement ni approuv\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu'est-ce que le tavapadon ? Le tavapadon est un comprim\u00e9","og:url":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/","og:image":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png","og:image:secure_url":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png","og:image:width":1000,"og:image:height":600,"article:published_time":"2026-09-28T21:05:12+00:00","article:modified_time":"2026-09-28T22:17:17+00:00","article:publisher":"https:\/\/facebook.com\/parkinsoncanada","twitter:card":"summary_large_image","twitter:site":"@parkinsoncanada","twitter:title":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir - Parkinson Canada","twitter:description":"La Food and Drug Administration (FDA) des \u00c9tats-Unis a approuv\u00e9 un nouveau m\u00e9dicament pour la maladie de Parkinson appel\u00e9 tavapadon (nom commercial JUVMO\u2122). Bien qu'il s'agisse d'une nouvelle encourageante, le tavapadon n'est actuellement ni approuv\u00e9 ni disponible au Canada. Voici ce que vous devez savoir. Qu'est-ce que le tavapadon ? Le tavapadon est un comprim\u00e9","twitter:creator":"@parkinsoncanada","twitter:image":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png"},"aioseo_meta_data":{"post_id":"62163","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2026-09-28 21:48:14","updated":"2026-09-28 22:42:50","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.parkinson.ca\/fr\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/\" title=\"Actualit\u00e9s\">Actualit\u00e9s<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tLa FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.parkinson.ca\/fr\/"},{"label":"Actualit\u00e9s","link":"https:\/\/www.parkinson.ca\/fr\/category\/actualites\/"},{"label":"La FDA approuve le tavapadon : ce que la communaut\u00e9 Parkinson au Canada doit savoir","link":"https:\/\/www.parkinson.ca\/fr\/la-fda-approuve-le-tavapadon-ce-que-la-communaute-parkinson-au-canada-doit-savoir\/"}],"_links":{"self":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts\/62163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/users\/235"}],"replies":[{"embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/comments?post=62163"}],"version-history":[{"count":5,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts\/62163\/revisions"}],"predecessor-version":[{"id":62170,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts\/62163\/revisions\/62170"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/media\/62165"}],"wp:attachment":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/media?parent=62163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/categories?post=62163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/tags?post=62163"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/audience?post=62163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}